Aptamer Group and ProAxsis Limited enter partnership to improve global logistics and stability of diagnostic tests
Back

19th August 2021

Aptamer Group and ProAxsis Limited enter partnership to improve global logistics and stability of diagnostic tests

Aptamer Group Limited, the developer of custom affinity ligands to enable the life science industry through its proprietary OptimerTM platform, and ProAxsis Limited, a commercial-stage respiratory diagnostics company, today announce a partnership to develop Optimer ligands for ProAxsis’s diagnostic assays.

 

Under the terms of the agreement, Aptamer Group will develop validated Optimer ligands against critical targets for ProAxsis’s diagnostic assays. ProAxsis will then assess Optimer performance within their current diagnostics assays, with the view to potentially replacing the antibodies in their commercial diagnostic assays. Aptamer Group will receive initial upfront payments with the potential for long-term royalty fees upon project success and the integration of the Optimer reagents into ProAxsis’s diagnostic assays.

Optimer ligands are nucleic acid-based affinity ligands that deliver high temperature stability which can remove the requirement for cold-chain supply to enable simple, cost-effective and more sustainable global logistics. As Optimers are manufactured without reliance on biological systems, they are highly batch consistent and offer increased security of supply compared to protein-based affinity ligands.

For the full story, please visit the Aptamer Group website.